Related Experiment Video
Updated: Jan 21, 2026

Detection of Viruses from Bioaerosols Using Anion Exchange Resin
Published on: August 22, 2018
4,8-Dimethylcoumarin Inhibitors of Intestinal Anion Exchanger slc26a3 (Downregulated in Adenoma) for Anti-Absorptive
Abstract:
The chloride/bicarbonate exchanger SLC26A3 (downregulated in adenoma) is expressed mainly in colonic epithelium, where it dehydrates the stool by facilitating the final step of chloride and fluid absorption. SLC26A3 inhibition has predicted efficacy in various types of constipation including that associated with cystic fibrosis. We previously identified, by high-throughput screening, 4,8-dimethylcoumarin inhibitors of murine slc26a3 with IC50 down to ∼150 nM. Here, we synthesized a focused library of forty-three 4,8-dimethylcoumarin analogues. Structure-activity studies revealed the requirement of 4,8-dimethylcoumarin-3-acetic acid for activity. The most potent inhibitors were produced by replacements at C7, including 3-iodo- (4az) and 3-trifluoromethyl- (4be), with IC50 of 40 and 25 nM, respectively. Pharmacokinetics in mice showed predicted therapeutic concentrations of 4az for >72 h following a single 10 mg/kg oral dose. 4az at 10 mg/kg fully normalized stool water content in a loperamide-induced mouse model of constipation. The favorable inhibition potency, selectivity within the SLC26 family, and pharmacological properties of 4az support its further preclinical development.
Insights
New 4,8-dimethylcoumarin analogues effectively inhibit the SLC26A3 chloride/bicarbonate exchanger, showing promise for treating constipation. Compound 4az demonstrated potent inhibition and normalized stool water content in mice.
Area of Science:
- Biochemistry
- Pharmacology
- Gastroenterology
Background:
- The SLC26A3 chloride/bicarbonate exchanger in colonic epithelium is crucial for stool dehydration.
- Inhibition of SLC26A3 is a potential therapeutic strategy for constipation, including that linked to cystic fibrosis.
Purpose of the Study:
- To synthesize and evaluate novel 4,8-dimethylcoumarin analogues as inhibitors of the SLC26A3 exchanger.
- To identify potent and pharmacokinetically suitable SLC26A3 inhibitors for preclinical development.
Main Methods:
- Synthesis of a focused library of 4,8-dimethylcoumarin analogues.
- Structure-activity relationship studies to determine key active moieties.
- In vitro inhibition assays (IC50 determination) and in vivo pharmacokinetic and efficacy studies in mouse models.
Main Results:
- Identified 4,8-dimethylcoumarin-3-acetic acid as essential for activity.
- Discovered potent inhibitors, including 3-iodo- (4az) and 3-trifluoromethyl- (4be) analogues, with IC50 values as low as 25 nM.
- Demonstrated favorable pharmacokinetics for 4az, achieving therapeutic concentrations for over 72 hours after a single oral dose.
- 4az normalized stool water content in a loperamide-induced constipation mouse model at 10 mg/kg.
Conclusions:
- Novel 4,8-dimethylcoumarin analogues, particularly 4az, exhibit potent SLC26A3 inhibition.
- Compound 4az possesses favorable pharmacological properties and efficacy in a preclinical constipation model.
- 4az warrants further investigation for its potential as a constipation therapeutic agent.
Related Concept Videos
Glucose Absorption Into the Small Intestine
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
Social Exchange Theory
Gas Exchange and Transport
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Drug Absorption: Factors Affecting GI Absorption

